

44. Use of a specifically reacting anti-GPIb (a) antibody for the discrimination between von Willebrand disease (vWD) type 1 and type 2 for carrying carrying out the steps of:

- a) detecting vWF activity in a test sample according to the method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib (a) (GPIb (a)) and ristocetin, or a functionally equivalent substance.
- b) determining the amount of vWF-antigen in said test sample;

45. Use of a specifically reacting anti-vWF antibody for the discrimination between von Willebrand disease (vWD) type 1 and type 2 carrying out the method of for carrying carrying out the steps of:

- a) detecting vWF activity in a test sample according to the method for detecting von-Willebrand factor (vWF) activity comprising assaying a sample in the presence of a soluble form or portion of glycoprotein Ib (a) (GPIb (a)) and ristocetin, or a functionally equivalent substance.
- b) determining the amount of vWF-antigen in said test sample

46. A kit for the discrimination between von Willebrand disease (vWD) type 1 and type 2 comprising at least one of the following:

- (a) a soluble form or portion of glycoprotein Ib (a) (GPIb (a))
- (b) ristocetin, or a functional equivalent substance;
- (c) an antibody selected from the group of a specifically reacting anti-GPIb a specifically reacting anti-vWF antibody and a specifically reacting anti-Factor VIII antibody
- (d) a solid support.

47. A kit according to claim 46 wherein the said soluble form or portion of glycoprotein Ib (a) (GPIb (a)) is a recombinant protein.


REMARKS

The above amendments are being made in order to eliminate multiple dependency and replace the claims with a new set of claims for consideration in the United States. Should any multiple dependency remain in the application, that is unintended, and the Patent and Trademark Office is requested to cancel any remaining multiple dependent claims without prejudice.

Examination of the application on its merits is awaited.

Dated: December 28, 2001

Respectfully submitted,


William M. Lee, Jr.
Registration No. 26,935

Lee, Mann, Smith, McWilliams,
Sweeney & Ohlson
P.O. Box 2786
Chicago, IL 60690-2786
(312) 368-1300
(312) 368-0034 (Fax)